Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIW815 (ADU-S100) plus PDR001 in advanced or metastatic solid tumors and lymphomas
NL-OMON48864Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ADU-S100 and spartalizumab in Nonhematologic neoplasms, lymphoma, melanoma and 2 more (2 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events, Changes in laboratory parameters and 3 more. Started Aug 2018; status: active, not recruiting.
02
Drugs
ADU-S100spartalizumab
03
Conditions
Nonhematologic neoplasmslymphomamelanomahead and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON48864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48864.